Surveys
NEN RADAR Survey Launch
23 October 2024
Help SPARC-Europe Enhance NEN Cancer Care
What is the NEN RADAR Survey?
Peptide receptor radionuclide therapy (PRRT), also known as radioligand therapy (RLT), can be a life-saving treatment for neuroendocrine neoplasm (NEN) cancer patients. However, many patients and healthcare professionals face significant challenges in accessing and understanding this treatment.
SPARC-Europe has launched the NEN Radioligand Awareness Research (NEN RADAR) to explore these challenges across Europe. The survey findings will inform evidence-based policy recommendations aimed at improving awareness, access, and availability of PRRT.
Who should participate?
We invite neuroendocrine cancer patients and healthcare professionals involved in their care to participate in this important survey.
Click your relevant below to take the survey now. The survey takes approximately 12 minutes to complete.
Research Studies
The NELMAS trial
(Study Title: NELMAS – An international multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE (Lutathera®) to best supportive care in patients after resection of neuroendocrine liver metastases) is now open for recruitment at Imperial College London. The trial is in set up process at numerous sites in UK and Ireland. Sites in EU will follow as soon as the EMA Ethics Approval for EU sites is in place. This is the first phase II surgical trial and the first RCT in adjuvant setting.
Note. The Christie Hospital is also in the process of setting up participation in NELMAS and will be led by PI Melissa Frizzerio. Date October 2024.
Petitions
None at present.
Share Your Views or Become Part of a Working Group
We often look for people with experience of Neuroendocrine Cancer to volunteer and take part in focus group discussions and surveys in order to gain insight into patients’ experience of their treatment and care. NCUK strives to be an evidenced-based organisation and your insights allow us to offer real-world evidence when we need it.